Nexus Biosystems Announces Acquisition of Aurora Biotechnologies
News Dec 09, 2009
NEXUS Biosystems, Inc. has announced the acquisition of Aurora Biotechnologies of Carlsbad, CA (Aurora), a developer of proprietary high performance microplates for use in sample storage, high-throughput screening, and cellular imaging.
“Combining the technologies and personnel of Aurora with Nexus will enable us to provide a wider spectrum of products for our current and future customers around the world,” said John Lillig, President and Chief Executive Officer of Nexus.
He continued, “With the recent launch of our automated -80°C BioStore line of sample management systems and our new XPeel microplate de-sealer, 2009 has been a strong growth year for Nexus. As we head into 2010 with the Aurora technologies, we are very excited about the opportunity to expand our product reach beyond automated sample management into high throughput biochemical, cell-based and genomic screening applications.”
Aurora serves the discovery research markets with optically pure consumable microplate products which enable high-throughput analysis of chemical compounds and cellular assays.
Aurora provides a broad range of high performance microplate designs, including 96-well, 384-well, 1,536-well and 3,456-well plates. These products are used daily in thousands of experiments in both private and public research institutions around the world.
When a protein named "Merlin" fails to do its job, people can develop slow-growing, life-disrupting auditory nerve tumors that can disrupt their hearing and balance. Now scientists at Cincinnati Children's have discovered much more about how Merlin does its job – by working behind the scenes through a network of more than 50 other proteins.READ MORE